BACKGROUND: During the period 1992-1993, the prevalence of hepatitis C virus (HCV) antibodies (anti-HCV) among US blood donors was 0.36%, but contemporary data on the prevalence of antibody to HCV and the prevalence of HCV RNA are lacking. METHODS: We performed a large, cross-sectional study of blood donors at 6 US blood centers during 2006-2007. Anti-HCV was measured with enzyme-linked immunosorbent assay followed by immunoblot, and HCV RNA was measured with nucleic acid testing. Adjusted odds ratios (aORs) were derived using multivariable logistic regression. RESULTS: Of 959,281 donors, 695 had anti-HCV detected (prevalence, 0.072%). Of those with anti-HCV, 516 (74%) had test results positive for HCV RNA, and 179 (26%) had test results that were negative for HCV RNA. Compared with the prevalence during the period 1992-1993, prevalence during 2006-2007 was lower and peaked in older age groups. Anti-HCV was associated with a body mass index (BMI) >30 (aOR, 0.6; 95% confidence interval [CI], 0.5-0.8), and among women, it was associated with higher gravidity (aOR for 5 vs 0 pregnancies, 3.2; 95% CI, 1.9-5.4). HCV RNA negative status was associated with black race (aOR, 0.4; 95% CI, 0.2-0.7), having more than a high school education (aOR, 1.6; 95% CI, 1.1-2.4), and BMI >30 (aOR, 2.4; 95% CI, 1.4-3.9). CONCLUSIONS: Decreasing HCV prevalence is most likely attributable to culling of seropositive donors and a birth cohort effect. We found new associations between anti-HCV prevalence and gravidity and obesity. Recently discovered genetic factors may underlie differences in HCV RNA clearance in black donors.
BACKGROUND: During the period 1992-1993, the prevalence of hepatitis C virus (HCV) antibodies (anti-HCV) among US blood donors was 0.36%, but contemporary data on the prevalence of antibody to HCV and the prevalence of HCV RNA are lacking. METHODS: We performed a large, cross-sectional study of blood donors at 6 US blood centers during 2006-2007. Anti-HCV was measured with enzyme-linked immunosorbent assay followed by immunoblot, and HCV RNA was measured with nucleic acid testing. Adjusted odds ratios (aORs) were derived using multivariable logistic regression. RESULTS: Of 959,281 donors, 695 had anti-HCV detected (prevalence, 0.072%). Of those with anti-HCV, 516 (74%) had test results positive for HCV RNA, and 179 (26%) had test results that were negative for HCV RNA. Compared with the prevalence during the period 1992-1993, prevalence during 2006-2007 was lower and peaked in older age groups. Anti-HCV was associated with a body mass index (BMI) >30 (aOR, 0.6; 95% confidence interval [CI], 0.5-0.8), and among women, it was associated with higher gravidity (aOR for 5 vs 0 pregnancies, 3.2; 95% CI, 1.9-5.4). HCV RNA negative status was associated with black race (aOR, 0.4; 95% CI, 0.2-0.7), having more than a high school education (aOR, 1.6; 95% CI, 1.1-2.4), and BMI >30 (aOR, 2.4; 95% CI, 1.4-3.9). CONCLUSIONS: Decreasing HCV prevalence is most likely attributable to culling of seropositive donors and a birth cohort effect. We found new associations between anti-HCV prevalence and gravidity and obesity. Recently discovered genetic factors may underlie differences in HCV RNA clearance in black donors.
Authors: E L Murphy; S M Bryzman; S A Glynn; D I Ameti; R A Thomson; A E Williams; C C Nass; H E Ownby; G B Schreiber; F Kong; K R Neal; G J Nemo Journal: Hepatology Date: 2000-03 Impact factor: 17.425
Authors: Shimian Zou; Edward P Notari; Susan L Stramer; Fawzi Wahab; Fatemeh Musavi; Roger Y Dodd Journal: Transfusion Date: 2004-11 Impact factor: 3.157
Authors: D L Thomas; J Astemborski; R M Rai; F A Anania; M Schaeffer; N Galai; K Nolt; K E Nelson; S A Strathdee; L Johnson; O Laeyendecker; J Boitnott; L E Wilson; D Vlahov Journal: JAMA Date: 2000-07-26 Impact factor: 56.272
Authors: B J W Hennig; S Hellier; A J Frodsham; L Zhang; P Klenerman; S Knapp; M Wright; H C Thomas; M Thursz; A V S Hill Journal: Genes Immun Date: 2002-09 Impact factor: 2.676
Authors: E L Murphy; S Bryzman; A E Williams; H Co-Chien; G B Schreiber; H E Ownby; R O Gilcher; S H Kleinman; L Matijas; R A Thomson; G J Nemo Journal: JAMA Date: 1996-04-03 Impact factor: 56.272
Authors: Jennifer C Lai; Jacqueline G O'Leary; James F Trotter; Elizabeth C Verna; Robert S Brown; R Todd Stravitz; Jeffrey D Duman; Lisa M Forman; Norah A Terrault Journal: Liver Transpl Date: 2012-05 Impact factor: 5.799
Authors: N Durier; E Yunihastuti; K Ruxrungtham; N V Kinh; A Kamarulzaman; D Boettiger; A Widhani; A Avihingsanon; B V Huy; S F B Syed Omar; A Sanityoso; S Chittmittrapap; N T H Dung; V Pillai; T Suwan-Ampai; M Law; A H Sohn; G Matthews Journal: J Viral Hepat Date: 2016-12-05 Impact factor: 3.728